Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?

Cancers, Free Full-Text

Pathways involved in natural progression of prostate cancer

Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors - ScienceDirect

Clovis trots out Rubraca prostate cancer partial win

Rucaparib or Physician's Choice in Metastatic Prostate Cancer

TRITON-3 Validates Rucaparib Monotherapy After a Prior ARPI but Before Chemotherapy in BRCA-Mutated mCRPC

Rucaparib provides better survival than usual care in metastatic prostate cancer - Hospital Pharmacy EuropeHospital Pharmacy Europe

Prostate cancer Nature Reviews Disease Primers

PDF) The TRITON programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

Rucaparib vs. Investigator choice - Problems with TRITON-3